• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病例报告:仑伐替尼在一名侵袭性低分化甲状腺癌患者新辅助治疗中的应用。

Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma.

机构信息

Endocrinology Unit, Policlinico San Martino, Genoa, 16132, Italy.

Pathology, Department of Integrated Surgical & Diagnostic Sciences, University of Genoa, Genoa, 16132, Italy.

出版信息

Future Oncol. 2019 Aug;15(24s):13-19. doi: 10.2217/fon-2019-0099. Epub 2019 Aug 6.

DOI:10.2217/fon-2019-0099
PMID:31385546
Abstract

We report a case of an elderly woman presenting with a huge cervical mass invading the tracheal lumen. Diagnosed as invasive poorly differentiated thyroid cancer, after an endotracheal biopsy, stenting and radiotherapy, it was judged eligible for total thyroidectomy, but surgery was delayed due to pulmonary thromboembolism. The patient was therefore treated with lenvatinib with a neoadjuvant intent until hemodynamic stability was obtained. Thyroidectomy and radioiodine therapy were then performed and the postdose scan revealed an area of modest uptake in the anterior part of the neck. The patient is now in a good clinical status and she continues her follow-up program without any adjuvant therapy.

摘要

我们报告了一例老年女性患者,其表现为巨大的颈椎肿块侵犯气管腔。诊断为侵袭性低分化甲状腺癌,在进行气管内活检、支架置入和放疗后,认为适合进行全甲状腺切除术,但由于肺血栓栓塞症而延迟了手术。因此,该患者使用仑伐替尼进行新辅助治疗,直到血流动力学稳定。随后进行了甲状腺切除术和放射性碘治疗,术后扫描显示颈部前部有一个适度摄取区域。目前患者临床状况良好,她继续接受随访,无需辅助治疗。

相似文献

1
Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma.病例报告:仑伐替尼在一名侵袭性低分化甲状腺癌患者新辅助治疗中的应用。
Future Oncol. 2019 Aug;15(24s):13-19. doi: 10.2217/fon-2019-0099. Epub 2019 Aug 6.
2
Long-term disease control and high clinical benefit in a patient with advanced thyroid cancer treated with lenvatinib.接受乐伐替尼治疗的晚期甲状腺癌患者的长期疾病控制和高临床获益。
Future Oncol. 2019 Aug;15(24s):3-6. doi: 10.2217/fon-2019-0092. Epub 2019 Aug 6.
3
Case Report: A New Entity: Multiple Differentiated Variant of Papillary Thyroid Carcinoma With Advanced Clinical Behavior.病例报告:一种新实体:具有晚期临床行为的多种分化变异型甲状腺乳头状癌。
Front Endocrinol (Lausanne). 2021 Apr 7;12:654638. doi: 10.3389/fendo.2021.654638. eCollection 2021.
4
[Effectiveness of Lenvatinib for Thyroid Cancer with Lung Metastases - Report of a Case].[仑伐替尼治疗甲状腺癌肺转移的疗效——1例报告]
Gan To Kagaku Ryoho. 2016 Nov;43(12):2121-2123.
5
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.索拉非尼作为不可切除性甲状腺乳头状癌新辅助治疗的潜在作用。
Arch Endocrinol Metab. 2018 Jun;62(3):370-375. doi: 10.20945/2359-3997000000046. Epub 2018 May 17.
6
Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.仑伐替尼联合放射性碘治疗晚期分化型甲状腺癌:病例报告及文献复习。
World J Surg Oncol. 2019 May 19;17(1):84. doi: 10.1186/s12957-019-1626-4.
7
Differentiated thyroid carcinoma: Incremental diagnostic value of I SPECT/CT over planar whole body scan after radioiodine therapy.分化型甲状腺癌:放射性碘治疗后I SPECT/CT相对于平面全身扫描的增量诊断价值。
Endocrine. 2017 Jun;56(3):551-559. doi: 10.1007/s12020-016-1086-3. Epub 2016 Sep 29.
8
Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.儿童甲状腺乳头状癌患者对乐伐替尼的反应。
Thyroid. 2018 Nov;28(11):1450-1454. doi: 10.1089/thy.2018.0064. Epub 2018 Oct 16.
9
Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice.评估 lenvatinib 治疗放射性碘难治性分化型甲状腺癌期间的 QTc 间期:来自真实临床实践的报告。
Future Oncol. 2019 Aug;15(24s):7-12. doi: 10.2217/fon-2019-0096. Epub 2019 Aug 16.
10
Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review.不可手术的甲状腺癌的新辅助仑伐替尼治疗:病例报告及文献复习。
Cancer Rep (Hoboken). 2022 Feb;5(2):e1466. doi: 10.1002/cnr2.1466. Epub 2021 Jun 8.

引用本文的文献

1
Neoadjuvant lenvatinib in a patient with invasive poorly differentiated thyroid cancer.一名侵袭性低分化甲状腺癌患者的新辅助乐伐替尼治疗
Ecancermedicalscience. 2025 Apr 25;19:1902. doi: 10.3332/ecancer.2025.1902. eCollection 2025.
2
Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.多激酶和高选择性激酶抑制剂在甲状腺癌患者新辅助治疗中的应用
Explor Target Antitumor Ther. 2025 Feb 13;6:1002291. doi: 10.37349/etat.2025.1002291. eCollection 2025.
3
Successful Salvage of Four Cases of Unresectable Papillary Thyroid Cancer Following Lenvatinib Administration.
乐伐替尼治疗后成功挽救4例不可切除性甲状腺乳头状癌
Cancer Diagn Progn. 2025 Jan 3;5(1):127-131. doi: 10.21873/cdp.10421. eCollection 2025 Jan-Feb.
4
Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma.加拿大多学科关于高危及放射性碘难治性甲状腺癌多模式管理的共识
Front Oncol. 2024 Nov 4;14:1437360. doi: 10.3389/fonc.2024.1437360. eCollection 2024.
5
The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review.低分化甲状腺癌(PDTC)个体化靶向治疗的漫长征程:一例病例报告及系统综述
J Pers Med. 2024 Jun 18;14(6):654. doi: 10.3390/jpm14060654.
6
Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.多激酶抑制剂/仑伐替尼联合局部区域治疗用于治疗碘难治性分化型甲状腺癌。
Cancer Med. 2022 Oct;11 Suppl 1(Suppl 1):40-46. doi: 10.1002/cam4.5108.
7
Poorly differentiated thyroid carcinoma: a clinician's perspective.低分化甲状腺癌:临床医生视角
Eur Thyroid J. 2022 Mar 24;11(2):e220021. doi: 10.1530/ETJ-22-0021.
8
Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review.不可手术的甲状腺癌的新辅助仑伐替尼治疗:病例报告及文献复习。
Cancer Rep (Hoboken). 2022 Feb;5(2):e1466. doi: 10.1002/cnr2.1466. Epub 2021 Jun 8.